Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | HRH2 | P25021 | 8/20 | 0.37 |
| ▸ | HRH1 | P35367 | 8/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1619682 | 0.86 | KCNH2 (0.45) | KCNH2HRH2HRH1HRH3MEN1 | |
| SCHEMBL4507239 | 0.86 | KCNH2 (0.43) | MMP2KCNH2MMP3HRH2HRH1 | |
| SCHEMBL1619268 | 0.85 | KCNH2 (0.51) | KCNH2HRH2HRH1HRH3MEN1 | |
| SCHEMBL4512493 | 0.85 | GPR119 (0.42) | MMP2KCNH2MMP3HRH2HRH1 | |
| SCHEMBL4504088 | 0.84 | KCNH2 (0.42) | MMP2KCNH2MMP3HRH2HRH1 | |
| SCHEMBL4508438 | 0.84 | MMP2 (0.45) | MMP2KCNH2MMP3HRH2HRH1 | |
| SCHEMBL1618052 | 0.84 | KCNH2 (0.48) | KCNH2HRH2HRH1HRH3MEN1 | |
| SCHEMBL4513184 | 0.84 | MMP2 (0.43) | MMP2KCNH2HRH1MEN1KCNA5 | |
| SCHEMBL4133581 | 0.84 | KCNH2 (0.46) | MMP2KCNH2MMP3HRH2HRH1 | |
| SCHEMBL4508382 | 0.84 | MMP2 (0.43) | MMP2KCNH2HRH1HRH3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319198-A2 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319198-A2 | Novel Oxabispidine Compounds And Their Use In The Treatment Of Cardiac Arrhythmias | RYR1, KCNH1, CACNA1E | MMP2 4639/4885KCNH2 14/4885MMP3 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.